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Poster Session-I 3720.3 months (range: 2.9 – 81.2). Relapse was treated with single
agent ATO in 22 (59.5%), with ATO1ATRA in 5(13.5%) and
with ATO1ATRA1anthracycline in 10 (27%). Thirty five
(94.5%) achieved CR (two early deaths). After remission induction,
a consolidation course of the same agents used in induction was ad-
ministered (ATO and ATRA were administered for 28 days), 34
(92%) achieved molecular remission after this course. All patients
who achieved molecular remission were offered an autologous
SCT. Fourteen patients opted to have an autologous SCT and
the remaining patients were scheduled to receive monthly cycles
of ATO as a single agent (n 5 14) or ATO1ATRA (n 5 7) for
6 months. The age, sex, duration of first CR, induction and consol-
idation regimen used to treat relapse was comparable between the
patients that underwent an autologous SCT and the remaining pa-
tients. Patients who underwent an autologous SCT were condi-
tioned with a conventional Bu/Cy regimen and received PBSC
graft with a median cell dose of 5.3  106 CD34/Kg (range: 3.54
– 9.24). There were no treatment related deaths following the au-
tologous SCT, one patient had an isolated CNS relapse 6 months
post transplant. There were no other relapses or deaths in this
group. Among the remaining patients who achieved CR but did
not have an autologous SCT (n 5 21), 16 relapsed and all except
one of these patients eventually died of progressive disease at me-
dian period of 1.6 months from second relapse (range: 0 – 42.6).
At a median follow up of 24 months, the 3-year Kaplan-Meier es-
timate of EFS among those who received an autologous SCT vs.
those that did not was 92.866.8 vs. 28.769.7 (log rank: P 5
0.003). Following remission induction with ATO based regimens
in patients with relapsed APL, consolidation with an autologous
SCT is associated with a significantly superior clinical outcome
in comparison to alternative ATO / ATRA based maintenance
regimens.90
EFFECT OF PLERIXAFOR (AMD 3100) PLUS G-CSF ON TUMOR CELL
MOBILIZATION AMONG PATIENTS WITH LYMPHOMA
DiPersio, J.F.1, Bridger, G.2, Calandra, G.2 1Washington University, St.
Louis, MO; 2Genzyme Corporation, Cambridge, MA
Introduction: Plerixafor used with G-CSF has been shown to
rapidly and predictably increase peripheral blood CD341
cells. This report evaluates the effect of G-CSF with or without
plerixafor on tumor cell mobilization in patients with lym-
phoma.
Methods: This is a retrospective evaluation of apheresis sam-
ples from patients with a diagnosis of BCL-2 positive non-Hodg-
kins lymphoma that were enrolled in either a pivotal Phase III
(3101) or Phase II (2101) study assessing the safety and efficacy
of plerixafor in hematopoietic stem cell mobilization. To assess
tumor cell mobilization, samples from apheresis products were
assayed by real-time quantitative polymerase chain reaction
(PCR) to quantify major breakpoint region (MBR) translocation
of the BCL-2 gene and normalized to B-actin. Standard curves
for the BCL-2 rearrangement and B-actin were generated to
quantify DNA levels within each sample. A result of undetectable
levels of the t(14;18) translocated BCL-2 gene indicated an ab-
sence of mobilized tumor cells.
Results: Apheresis samples from 11 BCL-2 positive lymphoma
patients, 8/ 298 patients enrolled in 3101 and 3/25 patients enrolled
in 2101, were evaluated for evidence of tumor cell mobilization. The
age of patients ranged from 47 to 66 years and majority of the pa-
tients were women (8/11 patients). Six patients were diagnosed
with follicular lymphoma while the remainder had diffuse large
cell lymphoma. Five patients received G-CSF alone and 6 patients
received a combination of G-CSF and plerixafor. Between 0.70 
106 CD341 cells/kg and 10.12  106 CD341 cells/kg were mobi-
lized within four apheresis days. Quantification by real-time PCR
demonstrated that 10 of the 11 patients had undetectable levels of
translocated BCL-2 in the leukapheresis product. One patient who
was treated with G-CSF alone had detectable levels of the BCL-2
translocation.
Conclusions: These findings are consistent with other phase II
clinical studies, which reported negligible tumor cell mobilization
after plerixafor treatment.91
PLERIXAFOR CAN PREDICTABLY MOBILIZE HEMATOPOIETIC STEM
CELLS IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED
WITH LENALIDOMIDE
Tarantolo, S.R.1, McSweeney, P.A.2, Micallef, I.N.M.3, Klein, L.M.4,
Calandra, G.5, Huebner, D.5 1Nebraska Methodist Hospital, Omaha,
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Introduction: Emerging literature suggests that lenalidomide
negatively affects the ability to collect CD341 cells in patients
with multiple myeloma (MM) undergoing hematopoietic stem cell
transplantation. The aim of this retrospective subgroup analysis is
to examine the efficacy of mobilization with plerixafor 1 G-CSF
(P1G) among patients previously treated with lenalidomide.
Methods: Patients with MM who participated in a phase III study
(3102) assessing the safety and efficacy of plerixafor in hematopoietic
stem cell mobilization or in a compassionate use program (CUP)
who received P1G and that had complete data on number of cycles
of lenalidomide and total CD34 1 cells collected were analyzed.
Trial designs of the aforementioned studies have been described pre-
viously (DiPersio ASH 2007, Calandra BMT 2007). Briefly, in study
3102, patients received P1G as a first line mobilization regimen,
whereas patients in the CUP received P1G as rescue therapy after
failing other mobilization regimens.
Results: Of the 148 patients randomized to P1G in 3102,
seven patients were previously treated with lenalidomide. In the
CUP database, 60/708 patients were previously treated with lena-
lidomide. Complete data on number of cycles of lenalidomide
and total CD341 cells collected was available for 27 patients;
five from 3102 and 22 from CUP. The mean age was
61.267.9 years and 14/27 (52%) of the patients were men.
The median number of lenalidomide cycles prior to mobilization
was four (range 1–20). Administration of P1G resulted in a me-
dian collection of 4.3  106 CD341 cells/kg. A total of 20/27
(74%) of the patients collected $ 2  106 CD341 cells/kg in
a median of two apheresis sessions. All the patients in 3102 col-
lected $ 2  106 CD341 cells/kg compared to 15/22 (68%) of
the patients in CUP. Overall, 22 (81.5%) patients proceeded to
transplant. Median time to neutrophil and platelet engraftment
was 11.5 days and 18 days, respectively.
Pooled DataStudy 3102
(n55) CUP (n522)from 3102
and CUP
(n527)Median Number of
Lenalidomide
Cycles (Range)4 (1–5) 4.5 (2–20) 4 (1–20)Median Collection
of CD 341
(106 cells/kg)
(Range)
14.8 (4.6–22.2) 3.29 (0.45–13.53) 4.3 (0.45–22.2)Percent of Patients
that Collected $
5  106 CD341
cells/kg4/5 (80%) 7/22 (32%) 11/27 (41%)Percent of Patients that
Collected $ 2  106
CD341 cells/kg5/5 (100%) 15/22 (68%) 20/27 (74%)Median Time (in days)
to Neutrophil
Engraftment (Range)12 (11–13) 11 (10–16) 11.5 (10–16)Median Time (in days)
to Platelet
Engraftment
(Range)18 (13–22) 18.5 (11–42) 18 (11–42)Conclusions: These preliminary results suggest that the majority
of patients with MM pretreated with lenalidomide can be success-
fully mobilized ($ 2  106 CD341 cells/kg) with P1G.
